FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis

– MAVENCLAD is the first oral MS treatment to provide two years of proven efficacy with a maximum of 20 days of treatment